Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Revenue: 2020-2025

Historic Revenue for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $458.6 million.

  • Apellis Pharmaceuticals' Revenue rose 132.98% to $458.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 42.11%. This contributed to the annual value of $781.4 million for FY2024, which is 97.02% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Revenue of $458.6 million as of Q3 2025, which was up 156.92% from $178.5 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Revenue high stood at $458.6 million for Q3 2025, and its period low was -$4.2 million during Q1 2021.
  • For the 3-year period, Apellis Pharmaceuticals' Revenue averaged around $180.2 million, with its median value being $172.3 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Revenue slumped by 75.88% in 2021 and then skyrocketed by 2,519.90% in 2022.
  • Apellis Pharmaceuticals' Revenue (Quarterly) stood at $60.3 million in 2021, then plummeted by 62.41% to $22.7 million in 2022, then surged by 545.89% to $146.4 million in 2023, then surged by 45.19% to $212.5 million in 2024, then soared by 132.98% to $458.6 million in 2025.
  • Its Revenue was $458.6 million in Q3 2025, compared to $178.5 million in Q2 2025 and $166.8 million in Q1 2025.